ICHR Earnings

ICHR reported its earnings on 2026-05-04, showcasing a revenue of 256.07M against an estimate of 253.07M, resulting in a 1.18% surprise. The EPS was 0.15, surpassing the expected 0.13 by 15.38%. The stock experienced a -2.8% price change on the earnings day and a 6.74% change over the next five days, reflecting market reactions to the results.

Following ICHR's earnings announcement on 2026-05-04, the stock price moved by -2.8% on the day of the release. Over the subsequent five days, it saw a 6.74% change. Historically, ICHR's stock price tends to shift by an average of 1.51% in the 10 days leading up to earnings and 6.67% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ICHR's annual revenue to reach 239.45M, while the EPS is projected at 0.12. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ICHR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ICHR's stock price typically moves by 1.51% in the 10 days before its earnings and 6.67% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.12 and revenue of 239.45M.

The earnings call summary reveals a decline in revenue and net income, despite a slight improvement in gross margin. The lack of discussion on operational updates, strategic initiatives, and returns, coupled with acknowledgment of significant risks, suggests uncertainty. The Q&A section didn't provide additional clarity. Given the market cap of $1.25 billion, the negative financial results and absence of optimistic guidance are likely to lead to a negative stock price movement of -2% to -8% over the next two weeks.